6 results on '"Saing, Sopany"'
Search Results
2. RESOLVE Trial_Statistical Analysis Plan_Pre-registration
- Author
-
Bagg, Matthew, Lo, Serigne, Cashin, Aidan, Herbert, Rob, O'Connell, Neil, Lee, Hopin, Hübscher, Markus, Wand, Benedict, O'Hagan, Edel, Rizzo, Rodrigo, Moseley, G., Stanton, Tasha, Maher, Christopher, Goodall, Stephen, Saing, Sopany, Zahara, Pauline, and McAuley, James
- Subjects
equipment and supplies ,human activities ,health care economics and organizations - Abstract
Pre-print of statistical analysis plan for the RESOLVE trial for people with chronic low back pain
- Published
- 2022
- Full Text
- View/download PDF
3. The RESOLVE Trial
- Author
-
Bagg, Matthew, Hübscher, Markus, Rabey, Martin, Wand, Benedict, O'Hagan, Edel, Moseley, G., Stanton, Tasha, Maher, Chris, Goodall, Stephen, Saing, Sopany, O'Connell, Neil, Luomajoki, Hannu, and McAuley, James
- Subjects
health services administration ,population characteristics ,equipment and supplies ,human activities ,health care economics and organizations - Abstract
A randomised clinical trial for chronic low back pain
- Published
- 2022
- Full Text
- View/download PDF
4. Effect of Graded Sensorimotor Retraining on Pain Intensity in Patients With Chronic Low Back Pain
- Author
-
Bagg, Matthew K., primary, Wand, Benedict M., additional, Cashin, Aidan G., additional, Lee, Hopin, additional, Hübscher, Markus, additional, Stanton, Tasha R., additional, O’Connell, Neil E., additional, O’Hagan, Edel T., additional, Rizzo, Rodrigo R. N., additional, Wewege, Michael A., additional, Rabey, Martin, additional, Goodall, Stephen, additional, Saing, Sopany, additional, Lo, Serigne N., additional, Luomajoki, Hannu, additional, Herbert, Robert D., additional, Maher, Chris G., additional, Moseley, G. Lorimer, additional, and McAuley, James H., additional
- Published
- 2022
- Full Text
- View/download PDF
5. Cost-effectiveness of one-stop-shop [18F]Fluorocholine PET/CT to localise parathyroid adenomas in patients suffering from primary hyperparathyroidism.
- Author
-
van Mossel, Sietse, Saing, Sopany, Appelman-Dijkstra, Natasha, Quak, Elske, Schepers, Abbey, Smit, Frits, de Geus-Oei, Lioe-Fee, and Vriens, Dennis
- Abstract
Purpose: We conducted a cost-effectiveness analysis in which we compared a preoperative [18F]Fluorocholine PET/CT-based one-stop-shop imaging strategy with current best practice in which [18F]Fluorocholine PET/CT is only recommended after negative or inconclusive [99mTc]Tc-methoxy isobutyl isonitrile SPECT/CT for patients suffering from primary hyperparathyroidism. We investigated whether the one-stop-shop strategy performs as well as current best practice but at lower costs.We developed a cohort-level state transition model to evaluate both imaging strategies respecting an intraoperative parathyroid hormone monitored treatment setting as well as a traditional treatment setting. The model reflects patients’ hospital journeys after biochemically diagnosed primary hyperparathyroidism. A cycle length of twelve months and a lifetime horizon were used. We conducted probabilistic analyses simulating 50,000 cohorts to assess joint parameter uncertainty. The incremental net monetary benefit and cost for each quality-adjusted life year were estimated. Furthermore, threshold analyses regarding the tariff of [18F]Fluorocholine PET/CT and the sensitivity of [99mTc]Tc-methoxy isobutyl isonitrile SPECT/CT were performed.The simulated long-term health effects and costs were similar for both imaging strategies. Accordingly, there was no incremental net monetary benefit and the one-stop-shop strategy did not result in lower costs. These results applied to both treatment settings. The threshold analysis indicated that a tariff of €885 for [18F]Fluorocholine PET/CT was required to be cost-effective compared to current best practice.Both preoperative imaging strategies can be used interchangeably. Daily clinical practice grounds such as available local resources and patient preferences should inform policy-making on whether a hospital should implement the one-stop-shop imaging strategy.Methods: We conducted a cost-effectiveness analysis in which we compared a preoperative [18F]Fluorocholine PET/CT-based one-stop-shop imaging strategy with current best practice in which [18F]Fluorocholine PET/CT is only recommended after negative or inconclusive [99mTc]Tc-methoxy isobutyl isonitrile SPECT/CT for patients suffering from primary hyperparathyroidism. We investigated whether the one-stop-shop strategy performs as well as current best practice but at lower costs.We developed a cohort-level state transition model to evaluate both imaging strategies respecting an intraoperative parathyroid hormone monitored treatment setting as well as a traditional treatment setting. The model reflects patients’ hospital journeys after biochemically diagnosed primary hyperparathyroidism. A cycle length of twelve months and a lifetime horizon were used. We conducted probabilistic analyses simulating 50,000 cohorts to assess joint parameter uncertainty. The incremental net monetary benefit and cost for each quality-adjusted life year were estimated. Furthermore, threshold analyses regarding the tariff of [18F]Fluorocholine PET/CT and the sensitivity of [99mTc]Tc-methoxy isobutyl isonitrile SPECT/CT were performed.The simulated long-term health effects and costs were similar for both imaging strategies. Accordingly, there was no incremental net monetary benefit and the one-stop-shop strategy did not result in lower costs. These results applied to both treatment settings. The threshold analysis indicated that a tariff of €885 for [18F]Fluorocholine PET/CT was required to be cost-effective compared to current best practice.Both preoperative imaging strategies can be used interchangeably. Daily clinical practice grounds such as available local resources and patient preferences should inform policy-making on whether a hospital should implement the one-stop-shop imaging strategy.Results: We conducted a cost-effectiveness analysis in which we compared a preoperative [18F]Fluorocholine PET/CT-based one-stop-shop imaging strategy with current best practice in which [18F]Fluorocholine PET/CT is only recommended after negative or inconclusive [99mTc]Tc-methoxy isobutyl isonitrile SPECT/CT for patients suffering from primary hyperparathyroidism. We investigated whether the one-stop-shop strategy performs as well as current best practice but at lower costs.We developed a cohort-level state transition model to evaluate both imaging strategies respecting an intraoperative parathyroid hormone monitored treatment setting as well as a traditional treatment setting. The model reflects patients’ hospital journeys after biochemically diagnosed primary hyperparathyroidism. A cycle length of twelve months and a lifetime horizon were used. We conducted probabilistic analyses simulating 50,000 cohorts to assess joint parameter uncertainty. The incremental net monetary benefit and cost for each quality-adjusted life year were estimated. Furthermore, threshold analyses regarding the tariff of [18F]Fluorocholine PET/CT and the sensitivity of [99mTc]Tc-methoxy isobutyl isonitrile SPECT/CT were performed.The simulated long-term health effects and costs were similar for both imaging strategies. Accordingly, there was no incremental net monetary benefit and the one-stop-shop strategy did not result in lower costs. These results applied to both treatment settings. The threshold analysis indicated that a tariff of €885 for [18F]Fluorocholine PET/CT was required to be cost-effective compared to current best practice.Both preoperative imaging strategies can be used interchangeably. Daily clinical practice grounds such as available local resources and patient preferences should inform policy-making on whether a hospital should implement the one-stop-shop imaging strategy.Conclusion: We conducted a cost-effectiveness analysis in which we compared a preoperative [18F]Fluorocholine PET/CT-based one-stop-shop imaging strategy with current best practice in which [18F]Fluorocholine PET/CT is only recommended after negative or inconclusive [99mTc]Tc-methoxy isobutyl isonitrile SPECT/CT for patients suffering from primary hyperparathyroidism. We investigated whether the one-stop-shop strategy performs as well as current best practice but at lower costs.We developed a cohort-level state transition model to evaluate both imaging strategies respecting an intraoperative parathyroid hormone monitored treatment setting as well as a traditional treatment setting. The model reflects patients’ hospital journeys after biochemically diagnosed primary hyperparathyroidism. A cycle length of twelve months and a lifetime horizon were used. We conducted probabilistic analyses simulating 50,000 cohorts to assess joint parameter uncertainty. The incremental net monetary benefit and cost for each quality-adjusted life year were estimated. Furthermore, threshold analyses regarding the tariff of [18F]Fluorocholine PET/CT and the sensitivity of [99mTc]Tc-methoxy isobutyl isonitrile SPECT/CT were performed.The simulated long-term health effects and costs were similar for both imaging strategies. Accordingly, there was no incremental net monetary benefit and the one-stop-shop strategy did not result in lower costs. These results applied to both treatment settings. The threshold analysis indicated that a tariff of €885 for [18F]Fluorocholine PET/CT was required to be cost-effective compared to current best practice.Both preoperative imaging strategies can be used interchangeably. Daily clinical practice grounds such as available local resources and patient preferences should inform policy-making on whether a hospital should implement the one-stop-shop imaging strategy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Effect of graded sensorimotor retraining on pain intensity in patients with chronic low back pain: a randomized clinical trial
- Author
-
Matthew K. Bagg, Benedict M. Wand, Aidan G. Cashin, Hopin Lee, Markus Hübscher, Tasha R. Stanton, Neil E. O’Connell, Edel T. O’Hagan, Rodrigo R. N. Rizzo, Michael A. Wewege, Martin Rabey, Stephen Goodall, Sopany Saing, Serigne N. Lo, Hannu Luomajoki, Robert D. Herbert, Chris G. Maher, G. Lorimer Moseley, James H. McAuley, Bagg, Matthew K, Wand, Benedict M, Cashin, Aidan G, Lee, Hopin, Hübscher, Markus, Stanton, Tasha R, O'Connell, Neil E, O'Hagan, Edel T, Rizzo, Rodrigo RN, Wewege, Michael A, Rabey, Martin, Goodall, Stephen, Saing, Sopany, Lo, Serigne N, Luomajoki, Hannu, Herbert, Robert D, Maher, Chris G, Moseley, G Lorimer, and McAuley, James H
- Subjects
Adult ,Male ,617.5: Orthopädische Chirurgie ,Minimal Clinically Important Difference ,Chronic pain ,Somatosensory disorders ,Neurological rehabilitation ,General & Internal Medicine ,Humans ,Low back pain ,Treatment outcome ,Middle aged ,Exercise ,11 Medical and Health Sciences ,Physical Therapy Modalities ,low back pain ,Original Investigation ,Pain Measurement ,Pain measurement ,Physical therapy modalities ,Minimal clinically important difference ,Neurological Rehabilitation ,General Medicine ,Middle Aged ,Pain management ,pain management ,Somatosensory Disorders ,treatment outcome ,Female ,chronic pain - Abstract
Refereed/Peer-reviewed Importance: The effects of altered neural processing, defined as altering neural networks responsible for perceptions of pain and function, on chronic pain remains unclear. Objective: To estimate the effect of a graded sensorimotor retraining intervention (RESOLVE) on pain intensity in people with chronic low back pain. Design, Setting, and Participants: This parallel, 2-group, randomized clinical trial recruited participants with chronic (>3 months) nonspecific low back pain from primary care and community settings. A total of 276 adults were randomized (in a 1:1 ratio) to the intervention or sham procedure and attention control groups delivered by clinicians at a medical research institute in Sydney, Australia. The first participant was randomized on December 10, 2015, and the last was randomized on July 25, 2019. Follow-up was completed on February 3, 2020. Interventions: Participants randomized to the intervention group (n = 138) were asked to participate in 12 weekly clinical sessions and home training designed to educate them about and assist them with movement and physical activity while experiencing lower back pain. Participants randomized to the control group (n = 138) were asked to participate in 12 weekly clinical sessions and home training that required similar time as the intervention but did not focus on education, movement, and physical activity. The control group included sham laser and shortwave diathermy applied to the back and sham noninvasive brain stimulation. Main Outcomes and Measures: The primary outcome was pain intensity at 18 weeks, measured on an 11-point numerical rating scale (range, 0 [no pain] to 10 [worst pain imaginable]) for which the between-group minimum clinically important difference is 1.0 point. Results: Among 276 randomized patients (mean [SD] age, 46 [14.3] years; 138 [50%] women), 261 (95%) completed follow-up at 18 weeks. The mean pain intensity was 5.6 at baseline and 3.1 at 18 weeks in the intervention group and 5.8 at baseline and 4.0 at 18 weeks in the control group, with an estimated between-group mean difference at 18 weeks of -1.0 point ([95% CI, -1.5 to -0.4]; P =.001), favoring the intervention group. Conclusions and Relevance: In this randomized clinical trial conducted at a single center among patients with chronic low back pain, graded sensorimotor retraining, compared with a sham procedure and attention control, significantly improved pain intensity at 18 weeks. The improvements in pain intensity were small, and further research is needed to understand the generalizability of the findings. Trial Registration: ANZCTR Identifier: ACTRN12615000610538.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.